

Applicants : David J. Pinsky et al.
U.S. Serial No : Not Yet Known
Filed : October 22, 2003
Page 3

In the claims:

Please cancel claims 3-20, 22-24, 26-28, 30 and 32 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a later-filed application. Accordingly, claims 1, 2, 21, 25, 29 and 31 are now pending and presented for examination in this application. The following listing of claims will replace all prior versions, and listings, of claims in the subject application:

1. (original) A method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a Factor IXa compound in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.
2. (original) A method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a Factor IXa compound and a pharmaceutically acceptable form of an indirect or direct fibrinolytic agent, each in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.
- 3.-20. (cancelled)
21. (original) A method for identifying a compound that is capable of improving an ischemic disorder in a subject which comprises:

Applicants : David J. Pinsky et al.
U.S. Serial No : Not Yet Known
Filed : October 22, 2003
Page 4

- a) administering the compound to an animal, which animal is a stroke animal model;
- b) measuring stroke outcome in the animal; and
- c) comparing the stroke outcome in step (b) with that of the stroke animal model in the absence of the compound so as to identify a compound capable of improving an ischemic disorder in a subject.

22.-24. (canceled)

25. (original) A method for treating a reperfusion injury in a subject which comprises administering to the subject a Factor IXa compound in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the reperfusion injury in the subject.

26.-28 (canceled)

29. (original) A method of inhibiting clot formation in a subject which comprises adding to blood an amount of an inactive recombinant mutein in an amount effective to inhibit clot formation in the subject but which does not significantly interfere with hemostasis when the blood is administered to a patient.

30. (canceled)

31. (original) An assay to monitor the effect of a Factor IXa compound administered to a subject to treat an ischemic disorder in the subject which comprises:

Applicants : David J. Pinsky et al.
U.S. Serial No : Not Yet Known
Filed : October 22, 2003
Page 5

- a) measuring the ischemic disorder in the subject;
- b) administering the factor IXa compound to the subject and measuring the ischemic disorder; and
- c) comparing the measurement of the ischemic disorder in step (b) with that measured in step (a) so as to monitor the effect of the Factor IXa compound.

32. (cancelled).